Doxribtimine

Doxribtimine

SCHEMBL3166229

Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O.Nc1nc2nc[nH]c2c(=O)[nH]1.Nc1nc2nc[nH]c2c(=O)[nH]1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

P

The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TK1 P04183 4/20 0.52
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TSHR P16473 2/20 0.51
TK2 O00142 1/20 0.51
ALB P02768 1/20 0.51
PKM P14618 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51
CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxribtimine SCHEMBL1052084 1.00 TK1 (0.52) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL3155784 1.00 TK1 (0.52) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL10409131 0.94 LMNA (0.47) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL3162205 0.92 LMNA (0.45) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL341619 0.90 LMNA (0.59) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL2195275 0.90 TK1 (0.52) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL28850774 0.87 LMNA (0.42) TK1LMNASMN1; SMN2TSHRALB
Doxribtimine SCHEMBL9465657 0.86 TK1 (0.51) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL1164058 0.86 TK1 (0.53) TK1LMNASMN1; SMN2TSHRTK2
Doxribtimine SCHEMBL8366525 0.86 TK1 (0.53) TK1LMNASMN1; SMN2TSHRTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741081-B2 Process for producing L-arginine, L-ornithine or L-citrulline KYOWA HAKKO BIO CO., LTD. (JP) 2010-06-22 US claimed
EP-1801206-B1 METHOD FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE KYOWA HAKKO BIO CO LTD (JP) 2010-03-24 EP claimed
US-20090123980-A1 PROCESS FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-14 US claimed
EP-1801206-A1 METHOD FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-06-27 EP claimed
US-7741081-B2 Process for producing L-arginine, L-ornithine or L-citrulline KYOWA HAKKO BIO CO., LTD. (JP) 2010-06-22 US disclosed
EP-1801206-B1 METHOD FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE KYOWA HAKKO BIO CO LTD (JP) 2010-03-24 EP disclosed
US-20090123980-A1 PROCESS FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-14 US disclosed
EP-1801206-A1 METHOD FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-06-27 EP disclosed